FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 505 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm May 20, 2021 Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... January 30, 2026 Load more HOT NEWS ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated...
